Form 4: Avidity Biosciences CEO Sarah Boyce Executes Stock Option and Sells Shares
SEC Form 4
Avidity Biosciences' CEO, Sarah Boyce, exercised stock options and sold shares on April 2, 2024, according to a recent SEC filing.
Summary
- On April 2, 2024, Sarah Boyce, the President and CEO of Avidity Biosciences, exercised a stock option to purchase 28,000 shares of common stock at a price of $1.24 per share.
- Simultaneously, Boyce sold 28,000 shares of common stock at a weighted-average price of $26.2471 per share, with individual sales ranging from $25.10 to $26.97.
- Following these transactions, Boyce directly owns 112,117 shares of Avidity Biosciences common stock, which includes 107,408 restricted stock units and 4,709 shares from the Employee Stock Purchase Plan.
- Boyce also holds options to purchase 873,015 shares of common stock, all of which are fully vested and exercisable.
Sentiment
Score: 5
Explanation: Neutral. This is a standard SEC filing related to insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares for personal financial management.
Stakeholder Impact
- The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
Key Dates
| Date | Description |
|---|---|
| 04/02/2024 | Date of stock option exercise and stock sale. |
| 04/03/2024 | Date of signature on the SEC filing. |
| 12/17/2029 | Expiration date of the stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.